 Proto-Oncogene Proteins c-abl
"Proto-Oncogene Proteins c-abl" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Non-receptor tyrosine kinases encoded by the C-ABL GENES. They are distributed in both the cytoplasm and the nucleus. c-Abl plays a role in normal HEMATOPOIESIS especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific N-terminal amino acids are deleted, releasing the kinase from negative regulation.
| Descriptor ID |
D016315
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.500 D12.776.624.664.700.167
|
| Concept/Terms |
Proto-Oncogene Proteins c-abl- Proto-Oncogene Proteins c-abl
- Proto Oncogene Proteins c abl
- c-abl, Proto-Oncogene Proteins
- Proto-Oncogene Proteins abl
- Proteins abl, Proto-Oncogene
- Proto Oncogene Proteins abl
- abl, Proto-Oncogene Proteins
- c-abl Proteins
- c abl Proteins
- abl Proto-Oncogene Products
- Products, abl Proto-Oncogene
- Proto-Oncogene Products, abl
- abl Proto Oncogene Products
- abl Proto-Oncogene Proteins
- Proto-Oncogene Proteins, abl
- abl Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-abl".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-abl".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-abl" by people in this website by year, and whether "Proto-Oncogene Proteins c-abl" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 | | 2006 | 1 | 1 | 2 | | 2008 | 1 | 0 | 1 | | 2014 | 0 | 2 | 2 | | 2015 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-abl" by people in Profiles.
-
Rizzo AN, Aman J, van Nieuw Amerongen GP, Dudek SM. Targeting Abl kinases to regulate vascular leak during sepsis and acute respiratory distress syndrome. Arterioscler Thromb Vasc Biol. 2015 May; 35(5):1071-9.
-
Letsiou E, Rizzo AN, Sammani S, Naureckas P, Jacobson JR, Garcia JG, Dudek SM. Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2015 Feb 01; 308(3):L259-69.
-
Wie SM, Adwan TS, DeGregori J, Anderson SM, Reyland ME. Inhibiting tyrosine phosphorylation of protein kinase Cd (PKCd) protects the salivary gland from radiation damage. J Biol Chem. 2014 Apr 11; 289(15):10900-8.
-
Wu W, Berg LJ. c-Abl, an additional tyrosine kinase required for T cell development and function. Cell Cycle. 2008 Dec 15; 7(24):3791.
-
Liu B, Bernard B, Wu JH. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. Proteins. 2006 Nov 01; 65(2):331-46.
-
Tokonzaba E, Capelluto DG, Kutateladze TG, Overduin M. Phosphoinositide, phosphopeptide and pyridone interactions of the Abl SH2 domain. Chem Biol Drug Des. 2006 Mar; 67(3):230-7.
-
O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6987-93.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|